Monte Rosa Therapeutics, Inc. (GLUE)

9.31 -1.00 (-9.70%) USD  |  NASDAQ  |  Nov 12, 16:00
9.80 +0.49 (+5.26%) After-Hours: 04:02
More

Monte Rosa Therapeutics EPS Diluted (Quarterly) : 0.0282 for Sept. 30, 2026

EPS Diluted (Quarterly) Chart

Historical EPS Diluted (Quarterly) Data

View and export this data back to 2020. Start Trial.
Date Value
September 30, 2026 0.0282
June 30, 2026 -0.4276
March 31, 2026 -0.4456
December 31, 2025 -0.7039
September 30, 2025 -0.3287
June 30, 2025 -0.1496
March 31, 2025 0.5652
December 31, 2024 0.2185
September 30, 2024 -0.2909
June 30, 2024 -0.4255
March 31, 2024 -0.5314
December 31, 2023 -0.5841
September 30, 2023 -0.7003
June 30, 2023 -0.7116
Date Value
March 31, 2023 -0.6492
December 31, 2022 -0.6296
September 30, 2022 -0.5846
June 30, 2022 -0.5672
March 31, 2022 -0.5136
December 31, 2021 -0.5037
September 30, 2021 -0.4268
June 30, 2021 -0.4126
March 31, 2021 -0.279
December 31, 2020 -0.4517
September 30, 2020 -0.147
June 30, 2020 -0.1219
March 31, 2020 -0.0978

EPS Diluted (Quarterly) Range, Past 5 Years

View EPS Diluted (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

EPS Diluted (Quarterly) Benchmarks

View EPS Diluted (Quarterly) Benchmarks
Start Trial
United Therapeutics Corp. 5.709
ACADIA Pharmaceuticals, Inc. 0.305
Alnylam Pharmaceuticals, Inc. 15.72
Anika Therapeutics, Inc. -0.0232
Savara, Inc. -0.1691

EPS Diluted (Quarterly) Related Metrics

Net Income (Quarterly) 3.063M
Revenue (Quarterly) 54.37M
Total Expenses (Quarterly) 51.30M
Enterprise Value 253.90M
Gross Profit Margin (Quarterly) 96.06%
Profit Margin (Quarterly) 5.63%
Earnings Yield -16.64%
Normalized Earnings Yield -16.64